N
15.30
-0.03 (-0.16%)
| 前收盘价格 | 15.32 |
| 收盘价格 | 15.10 |
| 成交量 | 256,868 |
| 平均成交量 (3个月) | 463,519 |
| 市值 | 1,989,359,488 |
| 市盈率 (P/E TTM) | 12.75 |
| 预期市盈率 (P/E Forward) | 35.21 |
| 价格/销量 (P/S) | 7.14 |
| 股市价格/股市净资产 (P/B) | 4.48 |
| 52周波幅 | |
| 利润日期 | 21 Aug 2024 - 22 Aug 2024 |
| 营业毛利率 | 60.66% |
| 营业利益率 (TTM) | 16.71% |
| 稀释每股收益 (EPS TTM) | 1.02 |
| 季度收入增长率 (YOY) | -61.30% |
| 季度盈利增长率 (YOY) | -83.20% |
| 流动比率 (MRQ) | 25.42 |
| 营业现金流 (OCF TTM) | 119.51 M |
| 杠杆自由现金流 (LFCF TTM) | 98.45 M |
| 资产报酬率 (ROA TTM) | 59.56% |
| 股东权益报酬率 (ROE TTM) | 75.51% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (AU) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | NEUREN FPO NZ [NEU] | - | - |
AIStockmoo 评分
-0.1
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 平均 | -0.13 |
|
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 13.29% |
| 机构持股比例 | 18.05% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合